Key Stats for Novo Nordisk Stock
- 52-Week Range: $35.66 – $63.66
- TIKR Target Price (Mid): ~$80
- TIKR Annualized IRR (Mid): ~14% per year
- Q2 2026 Adjusted Sales: DKK 78.5B (up 7% at CER)
- Wegovy Pill Cumulative Prescriptions: 5 million+
- LTM Gross Margin: 82.0%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
From the Most Valuable Company in Europe to a Stock Down More Than 50% From Its Peak
Novo Nordisk (NVO) is best known as the company behind Ozempic and Wegovy, but the business is broader than those two brand names.
The company is the global leader in diabetes care, with decades of insulin and GLP-1 development that give it manufacturing scale, regulatory expertise, and physician relationships that competitors cannot quickly replicate.
Its obesity franchise, built on the same semaglutide molecule, grew from essentially nothing to a multi-billion dollar business in just a few years. A rare disease division treating hemophilia and other serious conditions generates stable and growing revenue that most investors overlook.
The stock has lost more than 40% from its recent peak, not because the business has collapsed.
The market priced in perfection and then received a series of disappointments: a late-stage trial failure for next-generation CagriSema, aggressive US pricing pressure on injectable Wegovy, Medicaid coverage reductions for obesity medications, and the April 2026 launch of Eli Lilly’s competing oral obesity pill, Foundayo. The expectations reset was severe.
The drawdowns chart shows the full scope of the damage. NVO hit a max drawdown of 42.98% on March 27, 2026.
The stock partially recovered from that trough as Wegovy pill launch data came in better than expected, climbing through June and July, before pulling back again in August to sit roughly 25% below the recent high. The chart reflects a business going through a genuine transition, not a permanent impairment.
See historical and forward estimates for Novo Nordisk stock (It’s free!) >>>
The Wegovy Pill Changes the Equation, Even With Pricing Headwinds
The most important development of 2026 has been the Wegovy pill, an oral version of semaglutide launched in the US in January.
Management called it the strongest GLP-1 volume launch in history, and the data supports it. By Q1, the pill had generated 1.3 million prescriptions at nearly double the revenue analysts expected. By Q2, cumulative prescriptions since launch had crossed 5 million.
Weekly TRx for the pill reached around 265,000 in mid-July, with total weekly Wegovy scripts across pill and injectable approaching 575,000.
The pill matters for several reasons. It expands the addressable market to patients who cannot or will not self-inject, gives Novo a competing product against Foundayo in the oral obesity category, and CEO Mike Doustdar described a synergistic rather than cannibalizing effect on the injectable franchise. Novo’s Wegovy brand still commands around 65% of new US obesity prescriptions despite Foundayo’s April entry.
The revenue chart captures the transition period in USD terms. From $21.4 billion in FY2021, revenue grew to $48.9 billion in FY2025. Consensus estimates show a pullback to around $46.3 billion in FY2026 and roughly flat in FY2027, reflecting currency headwinds and US pricing erosion rather than volume decline.
Recovery begins in FY2028 as the pill scales internationally and new products contribute, with revenue projected toward $59 billion by FY2030. The near-term trough is visible and real, but the underlying volume trajectory remains intact.
See how Novo Nordisk performs against its peers in TIKR (It’s free!) >>>
What the Valuation Model Says at $45
The financial profile beneath all the noise is remarkable. Gross margins sit at 82%, EBIT margins at 49%, and return on invested capital at 44%. The company returned DKK 41.2 billion to shareholders in just the first half of 2026.
At around $45 per ADR share and roughly 11 times trailing earnings, NVO trades at a multiple that would seem modest for almost any pharmaceutical company of this quality, let alone the global leader in the most consequential drug category of the decade.
The TIKR valuation model works from a mid-case assumption of around 2% annual revenue growth in USD terms, reflecting the currency and pricing headwinds embedded in consensus, with net income margins expanding toward 37%.
The model arrives at a target of around $80, implying a potential total return of around 77% over roughly five and a half years, or about 14% annualized.
The scenario range runs from around 7% annualized in the low case to around 11% in the high case. The conservative revenue growth assumption likely understates upside if currency stabilizes or the pill scales faster than expected internationally.
Should You Buy NVO Stock?
Novo Nordisk is a durable, high-margin franchise going through a painful but navigable transition. The pricing headwinds on injectable Wegovy and Ozempic are real and persistent, but the pill launch has demonstrated that demand for semaglutide far exceeds what the injectable market could access alone.
International expansion of the pill across roughly 60 countries represents a growth runway that the current price does not appear to price in generously.
The risks deserve honest treatment. US drug pricing reform, Medicaid coverage changes, and Eli Lilly’s continued investment in oral obesity treatments represent genuine competitive threats. The ZEUS trial failure was a reminder that pipeline execution is not guaranteed. Currency movements between the Danish krone and the US dollar can meaningfully distort reported results.
And while the valuation is low by historical standards for NVO, reported earnings compression is still underway. Investors willing to hold through a difficult 2026 and 2027 will find the current price considerably more interesting than it was two years ago.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
Looking for New Opportunities?
- See which stocks billionaire investors are buying to follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
